<?xml version="1.0" encoding="utf-8" standalone="yes" ?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
  <channel>
    <title>mesothelioma</title>
    <link>/mesothelioma/genepanel/1493/</link>
      <atom:link href="/mesothelioma/genepanel/1493/index.xml" rel="self" type="application/rss+xml" />
    <description>mesothelioma</description>
    <generator>Source Themes Academic (https://sourcethemes.com/academic/)</generator><language>en-us</language><copyright>BioHub - UFPE</copyright><lastBuildDate>Sun, 09 Sep 2018 00:00:00 +0000</lastBuildDate>
    <image>
      <url>/mesothelioma/images/icon_hu7e12209333f22d741aca7d462871821f_9877_512x512_fill_lanczos_center_2.png</url>
      <title>mesothelioma</title>
      <link>/mesothelioma/genepanel/1493/</link>
    </image>
    
    <item>
      <title>CTLA4</title>
      <link>/mesothelioma/genepanel/1493/info/</link>
      <pubDate>Sun, 05 May 2019 00:00:00 +0100</pubDate>
      <guid>/mesothelioma/genepanel/1493/info/</guid>
      <description>


&lt;hr /&gt;
&lt;p&gt;cytotoxic T-lymphocyte associated protein 4&lt;/p&gt;
&lt;hr /&gt;
&lt;p align=&#34;left&#34; style=&#34;font-size:16px&#34;&gt;
&lt;p&gt;ENTREZID: &lt;a href=&#34;https://www.ncbi.nlm.nih.gov/gene/1493&#34; target=&#34;_blank&#34;&gt;1493&lt;/a&gt; | Type: Protein Coding |
Map: &lt;a href=&#34;https://www.ncbi.nlm.nih.gov/genome/gdv/browser/gene/?id=1493&#34; target=&#34;_blank&#34;&gt; 2q33.2&lt;/a&gt;&lt;br&gt;&lt;/p&gt;
OMIM: &lt;a href=&#39;https://omim.org/entry/616100&#39; target=&#39;_blank&#39;&gt;616100&lt;/a&gt; | &lt;a href=&#39;https://omim.org/entry/609755&#39; target=&#39;_blank&#39;&gt;609755&lt;/a&gt; | &lt;a href=&#39;https://omim.org/entry/601388&#39; target=&#39;_blank&#39;&gt;601388&lt;/a&gt; | &lt;a href=&#39;https://omim.org/entry/152700&#39; target=&#39;_blank&#39;&gt;152700&lt;/a&gt; | &lt;a href=&#39;https://omim.org/entry/140300&#39; target=&#39;_blank&#39;&gt;140300&lt;/a&gt; | &lt;a href=&#39;https://omim.org/entry/123890&#39; target=&#39;_blank&#39;&gt;123890&lt;/a&gt;
&lt;/p&gt;
&lt;br&gt;
&lt;p align=&#34;justify&#34; style=&#34;font-size:16px&#34;&gt;
&lt;strong&gt;Summary Entrez&lt;/strong&gt; &lt;br&gt;This gene is a member of the immunoglobulin superfamily and encodes a protein which transmits an inhibitory signal to T cells. The protein contains a V domain, a transmembrane domain, and a cytoplasmic tail. Alternate transcriptional splice variants, encoding different isoforms, have been characterized. The membrane-bound isoform functions as a homodimer interconnected by a disulfide bond, while the soluble isoform functions as a monomer. Mutations in this gene have been associated with insulin-dependent diabetes mellitus, Graves disease, Hashimoto thyroiditis, celiac disease, systemic lupus erythematosus, thyroid-associated orbitopathy, and other autoimmune diseases. [provided by RefSeq, Jul 2008] &lt;br&gt;&lt;br&gt;
&lt;/p&gt;
&lt;hr /&gt;
</description>
    </item>
    
    <item>
      <title>CTLA4</title>
      <link>/mesothelioma/genepanel/1493/gene_expression/</link>
      <pubDate>Sun, 05 May 2019 00:00:00 +0100</pubDate>
      <guid>/mesothelioma/genepanel/1493/gene_expression/</guid>
      <description>
&lt;script src=&#34;/mesothelioma/mesotheliomarmarkdown-libs/kePrint/kePrint.js&#34;&gt;&lt;/script&gt;


&lt;hr /&gt;
&lt;p&gt;cytotoxic T-lymphocyte associated protein 4&lt;/p&gt;
&lt;hr /&gt;
&lt;div id=&#34;gene-expression&#34; class=&#34;section level2&#34;&gt;
&lt;h2&gt;Gene Expression&lt;/h2&gt;
&lt;br&gt;
&lt;p style=&#34;font-size:12px&#34; align=&#34;center&#34;&gt;
&lt;strong&gt;Table 1.&lt;/strong&gt; CTLA4 expression overview from &lt;em&gt;human protein atlas database&lt;/em&gt;.
&lt;/p&gt;
&lt;table class=&#34;table table-striped&#34; style=&#34;width: auto !important; margin-left: auto; margin-right: auto;&#34;&gt;
&lt;thead&gt;
&lt;tr&gt;
&lt;th style=&#34;text-align:center;position: sticky; top:0; background-color: #FFFFFF;&#34;&gt;
ENSEMBL
&lt;/th&gt;
&lt;th style=&#34;text-align:center;position: sticky; top:0; background-color: #FFFFFF;&#34;&gt;
Tissue
&lt;/th&gt;
&lt;th style=&#34;text-align:center;position: sticky; top:0; background-color: #FFFFFF;&#34;&gt;
Protein
&lt;/th&gt;
&lt;th style=&#34;text-align:center;position: sticky; top:0; background-color: #FFFFFF;&#34;&gt;
mRNA
&lt;/th&gt;
&lt;/tr&gt;
&lt;/thead&gt;
&lt;tbody&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
ENSG00000163599
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
adipose tissue
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
NA
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1.5
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
ENSG00000163599
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
appendix
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
NA
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
23.5
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
ENSG00000163599
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
bone marrow
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
NA
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2.7
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
ENSG00000163599
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
breast
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
NA
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1.2
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
ENSG00000163599
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
colon
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
NA
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1.1
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
ENSG00000163599
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
esophagus
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
NA
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1.6
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
ENSG00000163599
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
gallbladder
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
NA
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
7.1
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
ENSG00000163599
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
lung
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
NA
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2.9
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
ENSG00000163599
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
lymph node
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
NA
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
31.9
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
ENSG00000163599
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
prostate
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
NA
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1.7
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
ENSG00000163599
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
rectum
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
NA
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
2.4
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
ENSG00000163599
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
small intestine
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
NA
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1.9
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
ENSG00000163599
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
spleen
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
NA
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
4.4
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
ENSG00000163599
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
stomach
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
NA
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1.7
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
ENSG00000163599
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
testis
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
NA
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
1.5
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
ENSG00000163599
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
tonsil
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
NA
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
15.3
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
ENSG00000163599
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
urinary bladder
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
NA
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
6.9
&lt;/td&gt;
&lt;/tr&gt;
&lt;/tbody&gt;
&lt;/table&gt;
&lt;/div&gt;
</description>
    </item>
    
    <item>
      <title>CTLA4</title>
      <link>/mesothelioma/genepanel/1493/gene_context/</link>
      <pubDate>Sun, 05 May 2019 00:00:00 +0100</pubDate>
      <guid>/mesothelioma/genepanel/1493/gene_context/</guid>
      <description>
&lt;script src=&#34;/mesothelioma/mesotheliomarmarkdown-libs/kePrint/kePrint.js&#34;&gt;&lt;/script&gt;


&lt;hr /&gt;
&lt;p&gt;cytotoxic T-lymphocyte associated protein 4&lt;/p&gt;
&lt;hr /&gt;
&lt;div id=&#34;gene-context-sentence&#34; class=&#34;section level2&#34;&gt;
&lt;h2&gt;Gene Context Sentence&lt;/h2&gt;
&lt;br&gt;
&lt;p style=&#34;font-size:12px&#34; align=&#34;center&#34;&gt;
&lt;strong&gt;Table 2.&lt;/strong&gt; Analysis of context sentence of CTLA4 gene in 6 abstracts.
&lt;/p&gt;
&lt;table class=&#34;table table-striped&#34; style=&#34;width: auto !important; margin-left: auto; margin-right: auto;&#34;&gt;
&lt;thead&gt;
&lt;tr&gt;
&lt;th style=&#34;text-align:center;position: sticky; top:0; background-color: #FFFFFF;&#34;&gt;
PMID
&lt;/th&gt;
&lt;th style=&#34;text-align:center;position: sticky; top:0; background-color: #FFFFFF;&#34;&gt;
Gene Context Sentence
&lt;/th&gt;
&lt;/tr&gt;
&lt;/thead&gt;
&lt;tbody&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;/mesothelioma/publication/24035405&#34; target=&#34;_blank&#34;&gt;24035405&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Monoclonal antibodies to cytotoxic T-lymphocyte antigen 4 (CTLA4) have therapeutic activity in different tumour types. […] We aimed to investigate the efficacy, safety, and immunological activity of the anti-CTLA4 monoclonal antibody, tremelimumab, in advanced malignant mesothelioma.
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;/mesothelioma/publication/25819643&#34; target=&#34;_blank&#34;&gt;25819643&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
CTLA4 blockade by tremelimumab 15 mg/kg every 90 days provided preliminary evidence of activity in patients with pretreated malignant mesothelioma; however, retrospective exposure-response analysis of data from patients with melanoma suggested that this schedule could result in underexposure to tremelimumab.
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;/mesothelioma/publication/29773326&#34; target=&#34;_blank&#34;&gt;29773326&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Tremelimumab, an anti-CTLA4 monoclonal antibody, initially showed good activity when used alone in patients with mesothelioma, but did not improve the overall survival of patients who failed on first-line or second-line chemotherapy compared with placebo in the DETERMINE study.
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;/mesothelioma/publication/31537897&#34; target=&#34;_blank&#34;&gt;31537897&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Since most malignant pleural mesotheliomas do not respond to anti-programmed cell death(-ligand)1 (PD-(L)1)/cytotoxic T-lymphocyte-associated protein 4 (CTLA4) therapy and given the recent finding of The Cancer Genome Atlas Study that pleural mesothelioma displays the highest expression of VISTA among all cancers studied, we examined VISTA expression in a large pleural mesothelioma cohort.
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;/mesothelioma/publication/31916017&#34; target=&#34;_blank&#34;&gt;31916017&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Twenty two patients received ICI with anti-CTLA4 or anti-PD-1 blockade in clinical trials, 58% had a response or stable disease for more than 6 m, with median progression-free survival (PFS) of 5.7 m (2.1-26.1 m).
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
&lt;a href=&#34;/mesothelioma/publication/32372095&#34; target=&#34;_blank&#34;&gt;32372095&lt;/a&gt;
&lt;/td&gt;
&lt;td style=&#34;text-align:center;&#34;&gt;
Third, we determined how L-PDT combined with immune checkpoint inhibitor anti-CTLA4 affected tumour growth in a murine MPM model. […] Also, compared to anti-CTLA4 that only affects tumour growth, the combination of L-PDT with anti-CTLA4 caused complete MPM regression in 37.5% of animals. […] The combination of L-PDT with immune checkpoint inhibitor anti-CTLA4 allows best tumour control and regression.
&lt;/td&gt;
&lt;/tr&gt;
&lt;/tbody&gt;
&lt;/table&gt;
&lt;hr /&gt;
&lt;/div&gt;
</description>
    </item>
    
    <item>
      <title>CTLA4</title>
      <link>/mesothelioma/genepanel/1493/clinvar/</link>
      <pubDate>Sun, 05 May 2019 00:00:00 +0100</pubDate>
      <guid>/mesothelioma/genepanel/1493/clinvar/</guid>
      <description>


&lt;hr /&gt;
&lt;p&gt;cytotoxic T-lymphocyte associated protein 4&lt;/p&gt;
&lt;hr /&gt;
&lt;div id=&#34;clinvar-summary&#34; class=&#34;section level2&#34;&gt;
&lt;h2&gt;ClinVar Summary&lt;/h2&gt;
&lt;br&gt;
&lt;p style=&#34;font-size:16px&#34; align=&#34;center&#34;&gt;
Under development
&lt;/p&gt;
&lt;hr /&gt;
&lt;/div&gt;
</description>
    </item>
    
    <item>
      <title>CTLA4</title>
      <link>/mesothelioma/genepanel/1493/geo/</link>
      <pubDate>Sun, 05 May 2019 00:00:00 +0100</pubDate>
      <guid>/mesothelioma/genepanel/1493/geo/</guid>
      <description>


&lt;hr /&gt;
&lt;p&gt;cytotoxic T-lymphocyte associated protein 4&lt;/p&gt;
&lt;hr /&gt;
&lt;div id=&#34;geo-dataset-summary&#34; class=&#34;section level2&#34;&gt;
&lt;h2&gt;GEO dataset Summary&lt;/h2&gt;
&lt;br&gt;
&lt;p style=&#34;font-size:16px&#34; align=&#34;center&#34;&gt;
Under development
&lt;/p&gt;
&lt;hr /&gt;
&lt;/div&gt;
</description>
    </item>
    
  </channel>
</rss>
